Ipsen Clears Hurdles to Get FDA Approval for First Drug for Ultra Rare Bone Disease

After numerous setbacks, Ipsen has won FDA approval for Sohonos (palovarotene), the first treatment for fibrodysplasia ossificans progressiva (FOP), a disease that causes connective tissue — muscle, tendons and ligaments — to gradually turn to bone.
Source: Drug Industry Daily